Heartflow, Inc. Announces Pricing of Upsized Initial Public Offering
Heartflow (NASDAQ: HTFL), an AI technology company focused on coronary artery disease (CAD), has announced the pricing of its upsized IPO. The company is offering 16,666,667 shares at $19.00 per share, expecting to raise approximately $316.7 million in gross proceeds.
Trading will commence on August 8, 2025, on the Nasdaq Global Select Market. The underwriters have a 30-day option to purchase up to 2.5 million additional shares. The IPO is expected to close on August 11, 2025, with J.P. Morgan, Morgan Stanley, and Piper Sandler serving as joint book-running managers.
Heartflow (NASDAQ: HTFL), un'azienda tecnologica specializzata in intelligenza artificiale focalizzata sulla malattia coronarica (CAD), ha annunciato il prezzo della sua IPO ampliata. La societ脿 offre 16.666.667 azioni a 19,00 $ per azione, prevedendo di raccogliere circa 316,7 milioni di dollari di proventi lordi.
Le negoziazioni inizieranno il 8 agosto 2025 sul Nasdaq Global Select Market. Gli underwriter hanno un'opzione di 30 giorni per acquistare fino a 2,5 milioni di azioni aggiuntive. L'IPO dovrebbe concludersi l'11 agosto 2025, con J.P. Morgan, Morgan Stanley e Piper Sandler come gestori congiunti del libro ordini.
Heartflow (NASDAQ: HTFL), una empresa tecnol贸gica de inteligencia artificial centrada en la enfermedad de la arteria coronaria (CAD), ha anunciado el precio de su oferta p煤blica inicial (IPO) ampliada. La compa帽铆a ofrece 16.666.667 acciones a 19,00 d贸lares por acci贸n, esperando recaudar aproximadamente 316,7 millones de d贸lares en ingresos brutos.
La negociaci贸n comenzar谩 el 8 de agosto de 2025 en el Nasdaq Global Select Market. Los suscriptores tienen una opci贸n de 30 d铆as para comprar hasta 2,5 millones de acciones adicionales. Se espera que la IPO cierre el 11 de agosto de 2025, con J.P. Morgan, Morgan Stanley y Piper Sandler como gestores conjuntos del libro de 贸rdenes.
Heartflow (NASDAQ: HTFL)電� 甏�靸侂彊毵レ頇�(CAD)鞐� 欷戩爯鞚� 霊� 鞚戈车歆�電� 旮办垹 須岇偓搿�, 歃濎暋霅� 旮办梾瓿店皽(IPO) 臧�瓴╈潉 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 16,666,667欤�毳� 欤茧嫻 19.00雼煬鞐� 鞝滉车頃橂┌, 齑� 鞎� 3鞏� 1,670毵� 雼煬鞚� 鞛愱笀鞚� 臁半嫭頃� 瓴冹溂搿� 鞓堨儊頃╇媹雼�.
瓯半灅电� 2025雲� 8鞗� 8鞚� 雮橃姢雼� 旮�搿滊矊 靺�霠夗姼 毵堨紦鞐愳劀 鞁滌瀾霅╇媹雼�. 鞚胳垬雼潃 30鞚缄皠 於旉皜搿� 250毵� 欤�旯岇 毵れ瀰頃� 靾� 鞛堧姅 鞓奠厴鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. IPO電� 2025雲� 8鞗� 11鞚检棎 毵堦皭霅� 鞓堨爼鞚措┌, J.P. Morgan, Morgan Stanley, Piper Sandler臧� 瓿惦彊 欤缄皠靷 彀胳棳頃╇媹雼�.
Heartflow (NASDAQ : HTFL), une entreprise technologique sp茅cialis茅e en intelligence artificielle ax茅e sur la maladie coronarienne (CAD), a annonc茅 le prix de son introduction en bourse 茅largie. La soci茅t茅 propose 16 666 667 actions au prix de 19,00 $ par action, esp茅rant lever environ 316,7 millions de dollars de produit brut.
Les n茅gociations d茅buteront le 8 ao没t 2025 sur le Nasdaq Global Select Market. Les souscripteurs disposent d'une option de 30 jours pour acheter jusqu'脿 2,5 millions d'actions suppl茅mentaires. L'introduction en bourse devrait se cl么turer le 11 ao没t 2025, avec J.P. Morgan, Morgan Stanley et Piper Sandler en tant que gestionnaires conjoints du livre d'ordres.
Heartflow (NASDAQ: HTFL), ein auf koronare Herzkrankheit (CAD) spezialisiertes KI-Technologieunternehmen, hat die Preisfestsetzung seines erweiterten B枚rsengangs bekanntgegeben. Das Unternehmen bietet 16.666.667 Aktien zu je 19,00 US-Dollar an und erwartet, etwa 316,7 Millionen US-Dollar Bruttoerl枚s zu erzielen.
Der Handel beginnt am 8. August 2025 am Nasdaq Global Select Market. Die Underwriter haben eine 30-t盲gige Option, bis zu 2,5 Millionen zus盲tzliche Aktien zu kaufen. Der B枚rsengang soll am 11. August 2025 abgeschlossen sein, wobei J.P. Morgan, Morgan Stanley und Piper Sandler als gemeinsame Bookrunner fungieren.
- None.
- 100% of shares offered are primary shares, indicating potential dilution for existing shareholders
- Additional dilution possible through 2.5M share underwriter option
Insights
Heartflow's upsized $316.7M IPO demonstrates strong investor appetite for AI-powered cardiac diagnostic technologies.
Heartflow's successful IPO represents a significant milestone for AI-based cardiovascular diagnostics. The company priced its offering at
The strong institutional backing is evident from the caliber of underwriters, with J.P. Morgan, Morgan Stanley, and Piper Sandler serving as joint book-running managers. This level of support typically indicates confidence in the company's business model and growth prospects.
Heartflow specializes in AI technology for coronary artery disease (CAD), positioning it at the intersection of two high-growth sectors: artificial intelligence and cardiovascular care. CAD remains one of the leading causes of mortality worldwide, creating substantial market opportunity. The company's AI solutions likely aim to improve diagnostic accuracy, reduce unnecessary invasive procedures, and potentially lower healthcare costs associated with CAD management.
The
MOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its upsized initial public offering of 16,666,667 shares of its common stock at a public offering price of
J.P. Morgan, Morgan Stanley and Piper Sandler are acting as joint book-running managers for the offering. Stifel and Canaccord Genuity are acting as co-managers for the offering.
A registration statement on Form S-1, including a prospectus, relating to these securities was declared effective by the U.S. Securities and Exchange Commission on August 7, 2025. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from J.P. Morgan, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at and ; Morgan Stanley, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at ; or Piper Sandler & Co., 350 North 5th Street, Suite 1300, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at 800-747-3924 or by email at .
This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Heartflow, Inc.
Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform 鈥� including Roadmap鈩� Analysis, FFRCT Analysis and Plaque Analysis 鈥� is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. Heartflow has helped clinicians manage over 400,000 patients worldwide.
Media Contact
Elliot Levy
Investor Contact
Nick Laudico
FAQ
What is the IPO price for Heartflow (HTFL) stock?
When will Heartflow (HTFL) start trading on Nasdaq?
How much money is Heartflow (HTFL) raising in its IPO?
Who are the underwriters for Heartflow's IPO?
What does Heartflow company do?
